Tilmicosin (Micotil) - FATAL in swine, horses

Tilmicosin, marketed under the brand name Micotil 300, is a semi-synthetic macrolide antibiotic developed specifically for the treatment of bovine respiratory disease in cattle and sheep. While effective for its approved indications, tilmicosin carries critical safety warnings that distinguish it from other macrolide antibiotics: it causes FATAL cardiovascular toxicity in swine, horses, and humans if administered to these species or accidentally injected into humans. This drug requires the highest level of respect and adherence to safety protocols of any commonly used veterinary antimicrobial. Understanding both its therapeutic benefits and its potentially lethal risks is essential for all personnel who handle or administer this medication.

The mechanism of action of tilmicosin involves binding to the 50S ribosomal subunit of susceptible bacteria, thereby inhibiting protein synthesis and preventing bacterial replication. This bacteriostatic action is characteristic of macrolide antibiotics and provides effective activity against the gram-positive and gram-negative respiratory pathogens responsible for bovine respiratory disease complex. Tilmicosin demonstrates excellent penetration into respiratory tissues, achieving lung concentrations substantially higher than plasma levels, which supports its efficacy against pathogens residing in the lower respiratory tract.

Tilmicosin is formulated as a sterile injectable solution at a high concentration of 300 mg/mL for subcutaneous administration only. The high concentration permits delivery of therapeutic doses in manageable injection volumes but also contributes to the severe consequences of accidental injection or misuse. The drug must NEVER be administered intravenously, as this route causes rapid fatal cardiovascular collapse even in approved species. The formulation is designed exclusively for subcutaneous use, and the importance of correct administration route cannot be overstated.

The regulatory status of tilmicosin reflects its unique safety profile. It is a prescription veterinary drug with restricted distribution requirements. The FDA approved tilmicosin for use only in cattle and sheep, with specific prohibition against use in swine, horses, and other species. Due to documented human fatalities following accidental self-injection, the product carries extensive human safety warnings, and access is limited to veterinary professionals and trained personnel who understand its risks. Every person who handles tilmicosin must be thoroughly educated about its potential for fatal toxicity in non-target species and humans.

The primary approved indication for tilmicosin is the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni in beef cattle and non-lactating dairy cattle. BRD represents the most economically significant disease in the cattle industry, causing losses through mortality, treatment costs, reduced growth performance, and decreased carcass quality. Tilmicosin's activity against the major bacterial pathogens of this disease complex, combined with its prolonged tissue concentrations, makes it an effective option for treatment of established respiratory infections in appropriate patient populations.

Beyond treatment of clinical disease, tilmicosin is also approved for control of respiratory disease in cattle at high risk of developing BRD. This metaphylactic or control indication is particularly valuable in feedlot operations where cattle arriving from auction markets, backgrounding operations, or direct ranch sources face significant stress and disease exposure during the transition period. By administering tilmicosin to groups of cattle identified as being at elevated risk based on source, transportation distance, commingling, and other factors, veterinarians can reduce the incidence and severity of respiratory disease outbreaks during the critical receiving period.

Tilmicosin is also approved for treatment of ovine respiratory disease (sheep pneumonia) associated with Mannheimia haemolytica and Pasteurella multocida. Respiratory disease in sheep, while less economically prominent than BRD in the overall livestock industry, causes significant losses in sheep flocks and requires effective treatment options. The pharmacokinetic profile of tilmicosin in sheep supports its use in this species with appropriate dose adjustment for the smaller body size of sheep compared to cattle.

The spectrum of activity of tilmicosin encompasses the primary bacterial pathogens of respiratory disease in cattle and sheep. Mannheimia haemolytica (formerly Pasteurella haemolytica biotype A) is the most important bacterial cause of acute fibrinous pneumonia in cattle and produces leukotoxins that contribute to the severe lung damage characteristic of this disease. Pasteurella multocida frequently acts as a secondary invader following viral infection or stress-induced immunosuppression. Histophilus somni causes both respiratory disease and systemic infections including thrombotic meningoencephalitis and myocarditis in cattle.

It is critical to emphasize what tilmicosin is NOT approved or safe for: use in swine causes FATAL cardiac arrhythmias and death. Use in horses causes similar FATAL cardiovascular toxicity. These are absolute contraindications, not merely label restrictions, and no circumstance justifies tilmicosin use in these species. Extra-label use in swine or horses is never permissible regardless of the clinical situation.

The approved dosage of tilmicosin for cattle is 10 mg per kilogram of body weight (10 mg/kg), administered as a single subcutaneous injection. Using the 300 mg/mL formulation, this translates to 1 mL per 30 kilograms (66 pounds) of body weight. Accurate weight determination is critical for proper dosing. In feedlot and ranch settings, cattle should be weighed or accurately estimated and grouped by weight class to ensure appropriate dosing. Underdosing may result in treatment failure, while overdosing increases the risk of adverse effects including injection site reactions and potentially cardiac effects.

For sheep, the approved dosage is also 10 mg per kilogram of body weight (10 mg/kg) by subcutaneous injection. Given the smaller body size of sheep, injection volumes are correspondingly smaller, but the same attention to accurate weight determination applies. Sheep should be individually assessed for weight to ensure proper dosing. Treatment should be administered in the neck region to minimize carcass trim impacts.

The subcutaneous route is the ONLY approved and safe route of administration for tilmicosin. The injection MUST be given subcutaneously in the neck region. INTRAVENOUS INJECTION IS FATAL - even in cattle, the approved species, intravenous administration causes rapid cardiovascular collapse and death. This is not a theoretical concern but a documented cause of animal and human deaths. Every person administering tilmicosin must understand that this drug can never be given intravenously under any circumstances.

Proper injection technique requires careful attention to avoid inadvertent intravascular administration. Before injecting, gentle aspiration should be performed to ensure the needle is not in a blood vessel. If blood is aspirated, the needle must be repositioned before injection. Injection should be made slowly and steadily. The maximum injection volume at any single site is 10 mL in cattle; for animals requiring larger volumes, the dose must be divided between two or more injection sites. In sheep, maximum volume per site should be proportionally reduced based on animal size.

A second dose may be administered if no improvement is noted 72 hours after the first injection. However, the need for retreatment should prompt reconsideration of the diagnosis and the possibility of antimicrobial resistance or other complicating factors. A maximum of two doses is recommended. Animals not responding to tilmicosin therapy should be evaluated for alternative diagnoses and treatment approaches rather than continuing with additional doses.

Withdrawal time requirements are critical for food safety compliance. For cattle, the meat withdrawal period is 28 days. For sheep, the meat withdrawal period is also 28 days. No animal should be slaughtered for human consumption within 28 days of the last tilmicosin treatment. Tilmicosin is not approved for use in female dairy cattle 20 months of age or older, or in lactating dairy cows, due to milk residue concerns. No milk withdrawal time has been established. Proper record-keeping documenting animal identification, treatment dates, dosages, and withdrawal dates is essential for regulatory compliance.

CRITICAL WARNING: Tilmicosin causes FATAL cardiovascular toxicity in swine, horses, and humans. This is not a side effect that occurs occasionally or at high doses - it is a predictable, dose-dependent lethal effect that occurs when this drug is administered to these species. Multiple human deaths have occurred following accidental self-injection with tilmicosin. The mechanism involves severe cardiac arrhythmias leading to cardiovascular collapse. Death can occur rapidly following injection, and treatment is often ineffective due to the speed and severity of the cardiovascular effects. This warning applies regardless of the dose injected.

In approved species (cattle and sheep) when administered correctly via the subcutaneous route, tilmicosin's most commonly observed side effects are injection site reactions. These local tissue responses include swelling, firmness, and discoloration at the injection site. The high concentration of the formulation (300 mg/mL) contributes to local tissue reaction. Studies have documented injection site reactions persisting for extended periods in some animals, with implications for carcass quality at slaughter. Injection in the neck region is mandatory to minimize trim losses from injection site lesions affecting valuable carcass cuts.

Even in cattle, cardiovascular effects of tilmicosin have been documented when the drug is administered at doses above the approved dose or inadvertently given by routes other than subcutaneous. Intravenous injection in cattle is fatal, causing the same cardiovascular collapse seen in swine and horses. Significant overdose via subcutaneous injection can also cause cardiac toxicity in cattle. Signs may include increased heart rate, cardiac arrhythmias, collapse, and death. These effects underscore the importance of accurate dosing and strict adherence to the subcutaneous administration route.

Other reported side effects in cattle at approved doses include transient decreases in feed intake and mild lethargy following treatment. These effects are typically mild and self-limiting, resolving within 24 to 48 hours. They may be difficult to distinguish from the underlying respiratory disease being treated. Gastrointestinal disturbances are possible but not commonly reported. Hypersensitivity reactions, while theoretically possible with any drug, are not a prominent feature of tilmicosin's adverse effect profile in cattle.

In sheep, the side effect profile is similar to that in cattle, with injection site reactions being the most commonly observed adverse effect. Cardiovascular effects of tilmicosin in sheep at approved doses have not been a prominent concern, but the same caution regarding accurate dosing and proper administration route applies. Any signs of cardiovascular distress following tilmicosin administration should be taken seriously and prompt immediate veterinary evaluation.

USE IN SWINE IS ABSOLUTELY CONTRAINDICATED - FATAL. Tilmicosin administration to swine causes rapid cardiovascular collapse and death. This is a consistent, predictable effect, not an idiosyncratic reaction. There is no safe dose of tilmicosin for swine. This contraindication is absolute and applies regardless of clinical circumstances. No extra-label use in swine is ever permissible. This prohibition must be clearly communicated to all personnel on any farm or facility where tilmicosin is present and where swine may also be housed.

USE IN HORSES IS ABSOLUTELY CONTRAINDICATED - FATAL. Tilmicosin causes the same fatal cardiovascular toxicity in horses as in swine. Horses are extremely sensitive to the cardiotoxic effects of tilmicosin, and death can occur rapidly following injection. There is no safe dose for horses. This contraindication applies to all equines including horses, ponies, donkeys, and mules. No circumstance justifies tilmicosin use in equines, and personnel must be educated about this absolute prohibition.

Intravenous injection is absolutely contraindicated even in approved species. While cattle and sheep can tolerate tilmicosin via subcutaneous injection at approved doses, intravenous administration is fatal in these species as well. The drug must never be given intravenously under any circumstances. If there is any possibility that a needle has entered a blood vessel during administration, the needle must be repositioned before injection. Accidental intravenous injection in cattle has resulted in fatalities.

Tilmicosin is contraindicated in animals with known hypersensitivity to the drug or other macrolide antibiotics. While hypersensitivity is less commonly documented than the cardiovascular toxicity concerns, animals with previous adverse reactions to tilmicosin or related macrolides should receive alternative antimicrobial therapy.

Use in female dairy cattle 20 months of age or older is contraindicated. This restriction prevents use in lactating dairy cows, where milk residues would create both public health and regulatory concerns. No milk withdrawal time has been established for tilmicosin. Dairy operations must ensure that tilmicosin is never administered to cattle that will enter the milking herd, and robust identification systems must be in place to prevent any violation of this restriction.

Drug interactions involving tilmicosin include important considerations related to both therapeutic effects and its unique toxicity profile. Concurrent administration of multiple macrolide antibiotics should be avoided, as this provides no therapeutic advantage and may increase the risk of adverse effects. Animals receiving tilmicosin should not simultaneously receive tulathromycin, tildipirosin, gamithromycin, tylosin, or other macrolide antibiotics. The extended tissue persistence of tilmicosin means that interactions could potentially occur even with medications given days after tilmicosin administration.

The interaction between tilmicosin and ionophore feed additives is a critical safety concern in cattle feeding operations. Ionophores including monensin, lasalocid, and laidlomycin are commonly incorporated into cattle rations as growth promotants and coccidiostats. The combination of tilmicosin with ionophores has been associated with increased toxicity, including fatal reactions. While cattle consuming ionophores can receive tilmicosin with appropriate caution, the combination requires careful consideration of the risks and potential for enhanced cardiotoxicity. Consultation with a veterinarian is essential when treating cattle receiving ionophore-containing feeds.

Potential antagonism between bacteriostatic and bactericidal antibiotics is a theoretical consideration with tilmicosin. As a macrolide, tilmicosin is bacteriostatic, and concurrent use with bactericidal agents might reduce efficacy. However, the clinical significance of this interaction in bovine respiratory disease treatment has not been definitively established. The decision to combine antimicrobials should be based on clinical judgment, taking into account disease severity, suspected pathogens, and resistance patterns.

Given tilmicosin's profound cardiovascular effects at toxic doses, caution is warranted when considering its use in animals that may have received other medications with cardiovascular effects. While documented interactions in this regard are limited, the potential for additive cardiotoxicity suggests careful evaluation when animals have been treated with drugs affecting cardiac function. This is particularly relevant given tilmicosin's narrow margin of safety and the consequences of enhanced cardiotoxicity.

HUMAN SAFETY WARNING: Accidental self-injection with tilmicosin can be FATAL. Multiple human deaths have been documented following accidental injection with this drug. The cardiovascular toxicity that makes tilmicosin lethal in swine and horses also applies to humans. Anyone who accidentally injects themselves with tilmicosin must seek emergency medical attention IMMEDIATELY - this is a life-threatening emergency. The product should be handled only by trained personnel who fully understand its risks. Tilmicosin should never be handled by persons with cardiovascular disease, and adrenaline (epinephrine) should be readily available when the drug is being administered.

Physical safety precautions during administration must be rigorous. Adequate animal restraint is essential to minimize the risk of accidental needle stick injuries. Automatic syringes with guarded needles or other safety-engineered devices should be considered to reduce injection hazards. Personnel should never work alone when administering tilmicosin. A second person should be present and prepared to summon emergency assistance if needed. The person administering the drug should have a clear path of retreat should animal movement create an injection hazard.

In the event of accidental human injection, emergency medical care must be sought immediately. While awaiting emergency services, the exposed individual should remain calm to minimize cardiovascular stress. Emergency medical responders should be informed that the drug is tilmicosin, a macrolide antibiotic veterinary product known to cause fatal cardiovascular toxicity in humans. Cardiovascular monitoring and support are the primary treatment considerations. The product label provides specific guidance for medical professionals treating tilmicosin exposure.

Food safety and residue avoidance require strict adherence to withdrawal time requirements. The 28-day meat withdrawal period for both cattle and sheep must be observed without exception. Proper identification of treated animals and accurate record-keeping are essential components of residue prevention programs. Operations should have systems in place to prevent slaughter of animals under withdrawal, including clear communication between treatment and marketing personnel.

Antimicrobial stewardship principles require that tilmicosin, like all antimicrobials, be used judiciously and only when bacterial respiratory disease is present or strongly suspected. Given the serious safety risks associated with tilmicosin handling, its use should be limited to situations where its benefits clearly outweigh the risks of handling the drug, and where safer alternatives are not equally effective. Veterinary guidance is essential for appropriate case selection and treatment decisions.

Tilmicosin storage requirements include maintaining the product at controlled room temperature between 20°C and 25°C (68°F to 77°F), with permitted excursions between 15°C and 30°C (59°F to 86°F). The product should be protected from freezing and from direct light exposure. Beyond these standard pharmaceutical storage requirements, tilmicosin requires additional security measures due to its potential for fatal human toxicity. The product should be stored in a locked cabinet or area with access limited to trained personnel who understand its hazards. Tilmicosin should never be stored in areas accessible to untrained personnel, children, or members of the public.

Handling of tilmicosin requires specific safety procedures beyond those for typical veterinary injectables. Personal protective equipment including impervious gloves and safety glasses should be worn during all handling and administration. The drug should be drawn up and administered using equipment designed to minimize needlestick injury risk. Automatic syringes, guarded needles, and other safety-engineered devices are strongly recommended. Multi-dose vial handling should employ aseptic technique, with the stopper disinfected before each needle entry. Needles should be changed between animals to prevent disease transmission and vial contamination.

Disposal of tilmicosin requires careful attention to both pharmaceutical and safety concerns. Unused product, empty containers, and administration equipment should be disposed of in accordance with all federal, state, and local regulations. Given the drug's toxicity, particular care should be taken to ensure that discarded product cannot be accessed by unauthorized persons or animals. Sharps must be disposed of in approved puncture-resistant containers and managed as regulated medical waste. The potential consequences of improper disposal, including the possibility of accidental human or animal exposure, require that disposal procedures be taken seriously and followed consistently.

Tilmicosin dosing is consistent across all cattle and sheep breeds at 10 mg/kg body weight, without breed-specific adjustments required. Clinical studies supporting product approval included cattle representing various British and Continental beef breeds as well as dairy breeds, establishing efficacy and safety across the genetic diversity of the cattle industry. For sheep, the product is approved without breed restrictions among commonly raised commercial breeds. The critical factor in all cases is accurate body weight determination to ensure proper dosing.

While breed-specific dosing adjustments are not required, practical considerations may influence tilmicosin use in different production systems and breed populations. Certain cattle breeds or types may be more commonly associated with feedlot populations where BRD pressure is highest and where tilmicosin use is most common. Dairy-beef crosses entering beef production systems face distinct health challenges compared to traditional beef breeds. These production system differences, while correlated with breed or type, influence treatment decisions through disease dynamics and management factors rather than pharmacokinetic differences.

The critical breed consideration for tilmicosin is the absolute prohibition against use in horses. This prohibition applies to all horse breeds without exception. Tilmicosin causes fatal cardiovascular toxicity in all equines, regardless of breed, size, or other characteristics. Similarly, the prohibition against use in swine applies to all swine breeds and types. There is no pig breed that tolerates tilmicosin - all are susceptible to its fatal cardiovascular effects. These prohibitions must be clearly understood by all personnel on any operation where tilmicosin is used and where horses or swine may be present.

Age and weight considerations apply across all breeds. Young calves and lambs may have different pharmacokinetics and disease susceptibilities compared to older animals. While tilmicosin is approved for cattle and sheep across age ranges, treatment decisions for very young animals should be made in consultation with a veterinarian. Accurate weight estimation is particularly challenging in young, growing animals but remains critical for appropriate dosing. Overdosing, even in approved species, increases the risk of cardiovascular effects that make tilmicosin uniquely dangerous among veterinary antimicrobials.

Within the macrolide antibiotic class, several alternatives to tilmicosin are available that offer effective respiratory disease treatment without the extreme toxicity risks. Tulathromycin (Draxxin) is a newer triamilide macrolide approved for cattle and swine with an excellent safety profile, including safety for use in swine where tilmicosin is fatal. Tildipirosin (Zuprevo) is similarly approved for both cattle and swine. Gamithromycin (Zactran) provides single-dose macrolide treatment for cattle. These newer macrolides have largely supplanted tilmicosin in many operations due to their improved safety profiles, particularly where swine are present or where human safety concerns are paramount.

Tylosin (Tylan) represents an older macrolide option with a long safety record, available in both injectable and feed-grade formulations. While tylosin's therapeutic applications differ somewhat from tilmicosin's primary respiratory disease indication, it provides an alternative macrolide option for appropriate cases. The safety profile of tylosin, while requiring normal veterinary drug handling precautions, does not carry the extreme human and animal toxicity concerns of tilmicosin.

Non-macrolide alternatives for bovine respiratory disease treatment include multiple drug classes. Florfenicol (Nuflor) offers broad-spectrum activity including against some macrolide-resistant pathogens. Fluoroquinolones including enrofloxacin (Baytril) and danofloxacin (Advocin) provide bactericidal options. Ceftiofur (Excede, Excenel) represents cephalosporin options. Tetracyclines including oxytetracycline have long histories of use in respiratory disease treatment. The selection among these alternatives depends on pathogen susceptibility, withdrawal time requirements, and operational factors. Given tilmicosin's unique safety risks, these alternatives may be preferred in many situations, particularly where handling safety concerns are prominent or where swine or horses share the premises.